Case Study #1– Animal Joint Mobility Supplements

Oral administration of Cannabidiol (CBD) increases Glucosamine (Gln) uptake in the synovial fluid in an animal model

We tested in vivo formulae containing of cannabidiol (CBD), glucosamine (Gln) and other beneficial active ingredients as dietary supplements targeted to treat osteoarthritis-related pain and difficulty in mobility. Previous attempts to administer Gln, a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, to reduce symptoms associated osteoarthritis have been thwarted by limited bioavailability, resulting in insufficient amounts of Gln in the target area, the synovial fluid (joint fluid). In our animal trials, we have demonstrated that Gln concentration in the synovial fluid is significantly increased when provided in combination with CBD and other ingredients. This increase is believed to be triggered by CBD’s ability to enhance permeability and consequent penetration via membranes and cell walls.